- Home
- KRMD vs IPHA Comparison
KRMD vs IPHA Comparison
Compare KRMD & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRMD | IPHA |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.0M | 160.7M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | KRMD | IPHA |
|---|---|---|
| Price | $4.33 | $1.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $6.00 | $5.75 |
| AVG Volume (30 Days) | ★ 152.8K | 14.6K |
| Earning Date | 04-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.67 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $33,646,463.00 | N/A |
| Revenue This Year | $24.39 | $28.31 |
| Revenue Next Year | $18.14 | N/A |
| P/E Ratio | $90.20 | ★ N/A |
| Revenue Growth | ★ 17.98 | N/A |
| 52 Week Low | $1.87 | $1.46 |
| 52 Week High | $6.61 | $2.63 |
Technical Indicators
Market Signals| Indicator | KRMD | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 32.59 | 33.61 |
| Support Level | $4.31 | N/A |
| Resistance Level | $4.34 | $1.88 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 0.01 | 14.98 |
Price Performance
Historical ComparisonAbout KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.